1. Home
  2. LOCL vs EQ Comparison

LOCL vs EQ Comparison

Compare LOCL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Local Bounti Corporation

LOCL

Local Bounti Corporation

HOLD

Current Price

$2.53

Market Cap

54.0M

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.20

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCL
EQ
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.0M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LOCL
EQ
Price
$2.53
$1.20
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
17.7K
510.3K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,978,000.00
$4,392,000.00
Revenue This Year
$36.93
N/A
Revenue Next Year
$82.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
31.61
N/A
52 Week Low
$1.18
$0.27
52 Week High
$5.75
$2.35

Technical Indicators

Market Signals
Indicator
LOCL
EQ
Relative Strength Index (RSI) 52.15 56.95
Support Level $2.48 $0.84
Resistance Level $2.70 $1.44
Average True Range (ATR) 0.21 0.12
MACD 0.03 0.06
Stochastic Oscillator 63.64 60.99

Price Performance

Historical Comparison
LOCL
EQ

About LOCL Local Bounti Corporation

Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: